The Trade Policy Staff Committee of the Office of the U.S. Trade Representative has published notice in the Federal Register on March 12, 2010, regarding the possible additions of pharmaceutical products and chemical intermediates to the existing duty-free pharmaceutical list. The current list is identified in the Pharmaceutical Appendix to the Harmonized Tariff Schedule of the United States. The list is the outcome of World Trade Organization (WTO) negotiations that resulted in the "zeroing" of duties arrived at pursuant to WTO negotiations.

A new round of WTO negotiations will begin in April 2010. The Trade Policy Staff Committee has requested comments by April 9, 2010.

For Further Information

If you would like further information about this Alert or are interested in participating in the announced review, please contact Brian S. Goldstein, any member of the International Practice Group, any member of the Pharmaceutical & Biotechnology Industry Group or the attorney in the firm with whom you are regularly in contact.

Disclaimer: This Alert has been prepared and published for informational purposes only and is not offered, nor should be construed, as legal advice. For more information, please see the firm's full disclaimer.